1.Clinical Observation of Xiere Xingpi Yin in Treatment of Simple Obesity and Effect on Obesity-related miRNAs
Yelin ZHU ; Yiwen HUANG ; Ke ZHANG ; Xianchang ZENG ; Zhenxiu LIU ; Hejin LAI ; Feng TAO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):177-185
ObjectiveTo observe the effects of Xiere Xingpi Yin (XRXPY) on the body mass and body fat distribution in patients with simple obesity, and to preliminarily explore whether the mechanism involves the regulation of specific obesity-related microRNAs (miRNAs). MethodsA randomized controlled trial design was employed to recruit patients with simple obesity diagnosed with the traditional Chinese medicine (TCM) syndrome of dampness-heat accumulating in the spleen. Using a randomized controlled trial design, 95 patients with simple obesity of dampness-heat encumbering the Spleen syndrome were recruited, after 3 were excluded, 92 were randomly assigned in a 1∶1 ratio by means of a random number table. On the basis of lifestyle intervention, the observation group received XRXPY granules, while the control group received a placebo. Serum samples and TCM symptom scores were collected before and after the 12-week observation period. Differences in body mass loss, body composition, lipid metabolism, and TCM symptom scores were compared between the groups. An obesity-related miRNA dataset was constructed by searching the Human MicroRNA Disease Database. Library construction, sequencing, and quality control were performed on 6 selected patients from each group to screen the differentially expressed miRNAs. The intersection of these miRNAs with the obesity-related miRNAs was verified by bioinformatics and correlation analysis. ResultsBaseline characteristics were comparable between the two groups before treatment. A total of 86 patients completed the study (42 cases in the observation group and 44 cases in the control group). The proportion of patients achieving ≥5% body weight reduction was significantly higher in the observation group than in the control group 81.0% (34/42) vs. 43.2% (19/44) (χ2=12.963, P<0.01). Compared with baseline within the observation group, body weight, waist circumference, and TCM syndrome score were significantly decreased (P<0.01), as were body fat percentage (P<0.01) and serum triglyceride level (P<0.05). Compared with the control group after treatment, waist circumference and TCM syndrome score were significantly lower in the observation group (P<0.01), and body weight showed a trend toward reduction. When changes from baseline were compared between the two groups, the magnitudes of decrease in body weight, waist circumference, and TCM syndrome score were all significantly greater in the observation group than in the control group (P<0.01). With respect to safety, no serious adverse events occurred in either group and no participant discontinued the study because of adverse events. Compared with baseline, alanine aminotransferase levels decreased significantly in both the control and observation groups (P<0.01), and urea decreased significantly in the observation group (P<0.01), indicating a favorable safety profile. Sequencing identified nine differentially expressed miRNAs. After intersecting with the obesity-related miRNA dataset (187 miRNAs), 3 miRNAs were identified: miR-221 (log2FC=-6.62, P=0.009), miR-29a (log2FC=6.33, P=0.016), and miR-10b (log2FC=-5.91, P=0.029). A total of 262 target genes of the 3 miRNAs were identified, which were significantly enriched in 67 pathways, including the lysine degradation pathway (P=0.001). Correlation analysis revealed a positive correlation between miR-221 and triglycerides (r=0.46, P=0.027), a negative correlation between miR-29a and waist-to-hip ratio (r=-0.41, P=0.047), and positive correlations of miR-10b with body fat percentage (r=0.49, P=0.014) and waist circumference (r=0.44, P=0.032). ConclusionXRXPY combined with lifestyle intervention can effectively reduce the body mass and improve body composition. The underlying mechanism may involve the regulation of the lysine degradation pathway via miR-221, miR-29a, and miR-10b, though further verification is required.
2.Clinical Observation of Xiere Xingpi Yin in Treatment of Simple Obesity and Effect on Obesity-related miRNAs
Yelin ZHU ; Yiwen HUANG ; Ke ZHANG ; Xianchang ZENG ; Zhenxiu LIU ; Hejin LAI ; Feng TAO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):177-185
ObjectiveTo observe the effects of Xiere Xingpi Yin (XRXPY) on the body mass and body fat distribution in patients with simple obesity, and to preliminarily explore whether the mechanism involves the regulation of specific obesity-related microRNAs (miRNAs). MethodsA randomized controlled trial design was employed to recruit patients with simple obesity diagnosed with the traditional Chinese medicine (TCM) syndrome of dampness-heat accumulating in the spleen. Using a randomized controlled trial design, 95 patients with simple obesity of dampness-heat encumbering the Spleen syndrome were recruited, after 3 were excluded, 92 were randomly assigned in a 1∶1 ratio by means of a random number table. On the basis of lifestyle intervention, the observation group received XRXPY granules, while the control group received a placebo. Serum samples and TCM symptom scores were collected before and after the 12-week observation period. Differences in body mass loss, body composition, lipid metabolism, and TCM symptom scores were compared between the groups. An obesity-related miRNA dataset was constructed by searching the Human MicroRNA Disease Database. Library construction, sequencing, and quality control were performed on 6 selected patients from each group to screen the differentially expressed miRNAs. The intersection of these miRNAs with the obesity-related miRNAs was verified by bioinformatics and correlation analysis. ResultsBaseline characteristics were comparable between the two groups before treatment. A total of 86 patients completed the study (42 cases in the observation group and 44 cases in the control group). The proportion of patients achieving ≥5% body weight reduction was significantly higher in the observation group than in the control group 81.0% (34/42) vs. 43.2% (19/44) (χ2=12.963, P<0.01). Compared with baseline within the observation group, body weight, waist circumference, and TCM syndrome score were significantly decreased (P<0.01), as were body fat percentage (P<0.01) and serum triglyceride level (P<0.05). Compared with the control group after treatment, waist circumference and TCM syndrome score were significantly lower in the observation group (P<0.01), and body weight showed a trend toward reduction. When changes from baseline were compared between the two groups, the magnitudes of decrease in body weight, waist circumference, and TCM syndrome score were all significantly greater in the observation group than in the control group (P<0.01). With respect to safety, no serious adverse events occurred in either group and no participant discontinued the study because of adverse events. Compared with baseline, alanine aminotransferase levels decreased significantly in both the control and observation groups (P<0.01), and urea decreased significantly in the observation group (P<0.01), indicating a favorable safety profile. Sequencing identified nine differentially expressed miRNAs. After intersecting with the obesity-related miRNA dataset (187 miRNAs), 3 miRNAs were identified: miR-221 (log2FC=-6.62, P=0.009), miR-29a (log2FC=6.33, P=0.016), and miR-10b (log2FC=-5.91, P=0.029). A total of 262 target genes of the 3 miRNAs were identified, which were significantly enriched in 67 pathways, including the lysine degradation pathway (P=0.001). Correlation analysis revealed a positive correlation between miR-221 and triglycerides (r=0.46, P=0.027), a negative correlation between miR-29a and waist-to-hip ratio (r=-0.41, P=0.047), and positive correlations of miR-10b with body fat percentage (r=0.49, P=0.014) and waist circumference (r=0.44, P=0.032). ConclusionXRXPY combined with lifestyle intervention can effectively reduce the body mass and improve body composition. The underlying mechanism may involve the regulation of the lysine degradation pathway via miR-221, miR-29a, and miR-10b, though further verification is required.
3.The preventive and therapeutic effects of three ethanol extracts derived from three sources of Stellera chamaejasme L. on imiquimod-induced psoriasis in mice
Ying PENG ; Xin LIU ; Yiwen NIE ; Xinhe WANG ; Hua NIAN ; Jianyong ZHU
Journal of Pharmaceutical Practice and Service 2026;44(10):502-507
Objective To investigate the preventive and therapeutic effects of ethanol extracts derived from three sources of traditional Chinese medicine: Stellera chamaejasme L., Euphorbia fischeriana Steud. and Euphorbia kansuensis Prokh., on imiquimod (IMQ)-induced psoriasis in mice. Methods Thirty-six male BALB/c mice were randomly divided into the following 6 groups with 6 mice in each group: blank control, model, Stellera chamaejasme, Euphorbia fischeriana, Euphorbia kansuensis, and calcipotriol. Psoriasis area and severity index(PASI) scores were used to record the changes of skin lesions in every group; Hematoxylin-eosin(HE) staining was used to observe the pathological morphology of skin and measure the thickness of the epidermis. Immunohistochemistry was used to detect the expression of nuclear antigen Ki67 in the skin tissues of mice. Results Compared with the model group, the three kinds of ethanol extracts could reduce the PASI score, inhibit epidermal thickening, and decrease expression of Ki67 in the psoriasis mice. Among them, the therapeutic effect of Stellera chamaejasme was the most significant and it was better than the commonly used topical drug calcipotriol. Conclusion The ethanol extract of Stellera chamaejasme had good anti-psoriatic activity, which could inhibit the abnormal proliferation of keratinocytes, reduce the expression of Ki67, and significantly improve psoriasis-like skin lesions.
4.Practices and considerations on the free HPV vaccination program for eligible girls in Zhejiang Province under the global initiative to accelerate cervical cancer elimination
Yingping CHEN ; Xuan DENG ; Ying WANG ; Yiwen ZHU ; Yuxia LIANG ; Hanqing HE ; Shenyu WANG
Chinese Journal of Preventive Medicine 2025;59(9):1495-1502
Against the backdrop of the global acceleration of cervical cancer elimination, China has been promoting pilot programs offering free or subsidized HPV vaccination for eligible girls. In 2022, Zhejiang Province initiated a free bivalent HPV vaccination program for eligible girls, expanding from pilot areas to the whole province. Through key measures such as effective multi-sectoral collaboration, full financial support, comprehensive health education and high-quality vaccination services, the program was successfully implemented. However, challenges were encountered during the implementation of the program, including difficulties in target population definition and HPV vaccine selection, as well as significant gap between vaccination intention and behavior. This article systematically analyzes the practices and challenges faced by Zhejiang Province, and proposes corresponding strategies and suggestions based on the best practices both domestically and internationally. It aims to provide references for the implementation of similar programs in other regions or even integrating HPV vaccine into the immunization program.
5.Comparative analysis of free HPV vaccination programs across countries with different income levels worldwide: from implementation to evaluation
Yiwen ZHU ; Yingping CHEN ; Yuxia LIANG ; Shenyu WANG
Chinese Journal of Preventive Medicine 2025;59(9):1503-1511
Since the introduction of human papillomavirus (HPV) vaccines, countries around the world have actively promoted large-scale vaccination with HPV vaccines to improve their coverage for target populations. This study conducts a multidimensional analysis to quantify the policies, implementation models and evaluation outcomes of the free HPV vaccination program across countries at high, upper-middle and lower-middle income levels. The results reveal distinct patterns in implementation and evaluation among these countries. The results also suggest that China can learn from successful international experiences to explore more effective vaccination strategies to increase coverage. In parallel, it is essential to develop a scientifically grounded evaluation framework and conduct systematic evaluations to effectively support the continuous implementation of the free HPV vaccination program for target populations in China. Furthermore, China may consider incorporating appropriate HPV vaccines into the National Immunization Program and dynamically adjusting vaccine types as needed to accelerate the elimination of cervical cancer.
6.Practices and considerations on the free HPV vaccination program for eligible girls in Zhejiang Province under the global initiative to accelerate cervical cancer elimination
Yingping CHEN ; Xuan DENG ; Ying WANG ; Yiwen ZHU ; Yuxia LIANG ; Hanqing HE ; Shenyu WANG
Chinese Journal of Preventive Medicine 2025;59(9):1495-1502
Against the backdrop of the global acceleration of cervical cancer elimination, China has been promoting pilot programs offering free or subsidized HPV vaccination for eligible girls. In 2022, Zhejiang Province initiated a free bivalent HPV vaccination program for eligible girls, expanding from pilot areas to the whole province. Through key measures such as effective multi-sectoral collaboration, full financial support, comprehensive health education and high-quality vaccination services, the program was successfully implemented. However, challenges were encountered during the implementation of the program, including difficulties in target population definition and HPV vaccine selection, as well as significant gap between vaccination intention and behavior. This article systematically analyzes the practices and challenges faced by Zhejiang Province, and proposes corresponding strategies and suggestions based on the best practices both domestically and internationally. It aims to provide references for the implementation of similar programs in other regions or even integrating HPV vaccine into the immunization program.
7.Comparative analysis of free HPV vaccination programs across countries with different income levels worldwide: from implementation to evaluation
Yiwen ZHU ; Yingping CHEN ; Yuxia LIANG ; Shenyu WANG
Chinese Journal of Preventive Medicine 2025;59(9):1503-1511
Since the introduction of human papillomavirus (HPV) vaccines, countries around the world have actively promoted large-scale vaccination with HPV vaccines to improve their coverage for target populations. This study conducts a multidimensional analysis to quantify the policies, implementation models and evaluation outcomes of the free HPV vaccination program across countries at high, upper-middle and lower-middle income levels. The results reveal distinct patterns in implementation and evaluation among these countries. The results also suggest that China can learn from successful international experiences to explore more effective vaccination strategies to increase coverage. In parallel, it is essential to develop a scientifically grounded evaluation framework and conduct systematic evaluations to effectively support the continuous implementation of the free HPV vaccination program for target populations in China. Furthermore, China may consider incorporating appropriate HPV vaccines into the National Immunization Program and dynamically adjusting vaccine types as needed to accelerate the elimination of cervical cancer.
8.Research progress in the immunomodulatory mechanisms mediated by galectin-9
Yiwen XU ; Jun LING ; Bing ZHU ; Limei YU ; Shaoli YOU
Chinese Journal of Microbiology and Immunology 2025;45(4):355-360
Galectin-9 (Gal-9), a member of the β-galactoside-binding lectin family, is widely expressed in various tissues and cells. It can specifically bind to multiple glycoprotein receptors, including the receptors of Tim-3, CD44, 4-1BB/CD137, and Dectin-1, thereby regulating the activity of immune cells and participating in crucial physiological and pathological processes such as immune regulation and tumor development. Given its role in immunomodulation, Gal-9 is considered a potential target for immunotherapy, showing promising prospects in the treatment of various diseases, including autoimmune disorders, transplantation rejection, pregnancy complications, inflammation, infection, and cancer. This review summarizes the biological effects mediated by Gal-9 upon binding to its receptors, which may help to explore the potential application value of Gal-9 in clinical diagnosis and therapy.
9.Comparison of clinical outcomes between latissimus dorsi flap with implant and mesh with implant for immediate breast reconstruction: a BREAST-Q assessment
Tinghong XIANG ; Lu YIN ; Tianyi NI ; Yiwen GAO ; Yingying WANG ; Xianglong ZU ; Shujie RUAN ; Wei YAN ; Zhechen ZHU ; Jingping SHI
Chinese Journal of Plastic Surgery 2025;41(7):710-718
Objective:To compare the clinical outcomes of immediate breast reconstruction using latissimus dorsi flap with implant versus mesh with implant based on BREAST-Q evaluation.Methods:From the clinical database of the First Affiliated Hospital of Nanjing Medical University, the patients who underwent immediate breast reconstruction after total mastectomy from January 2020 to December 2023 were selected as the research subjects. All breast reconstruction surgeries were performed by the same surgeon. Patients were divided into two groups according to surgical methods: the latissimus dorsi muscle flap combined with implant immediate breast reconstruction group (LD group) and the mesh combined with implant immediate breast reconstruction group (mesh group). Patients were followed up in outpatient clinics or by telephone one year after surgery. The BREAST-Q was used to evaluate the surgical outcomes of both groups from four dimensions: psychosocial well-being, sexual well-being, chest-physical well-being, and breast satisfaction. The score range for each dimension was 0-100, with higher scores indicating greater patient satisfaction with quality of life and surgical outcomes. Statistical analysis was performed using SPSS 22.0 software. Normally distributed measurement data were expressed as Mean ± SD, and comparisons between the two groups were performed using independent sample t-test. Count data were expressed as number of cases and percentages, and comparisons between groups were performed using chi-square test or Fisher’s exact test. P<0.05 was considered statistically significant. Results:A total of 123 patients were included, with 59 patients in the LD group and 64 patients in the mesh group. In the LD group, the mean age was (37.7±7.0) years, body mass index (BMI) was (22.6±2.6) kg/m 2, and clinical tumor staging showed 2, 22, 30, and 5 cases for stages 0, Ⅰ, Ⅱ, and Ⅲ, respectively. In the mesh group, the mean age was (39.1±7.0) years, BMI was (22.6±2.8) kg/m 2, and clinical tumor staging showed 1, 25, 38, and 0 cases for stages 0, Ⅰ, Ⅱ, and Ⅲ, respectively. There were no statistically significant differences between the two groups in baseline characteristics including age, BMI, and clinical tumor staging (all P>0.05). One year after surgery, the BREAST-Q result showed no statistically significant differences between the LD group and mesh group in psychosocial well-being [(83.0±19.8) points vs. (80.8±19.3) points] and sexual well-being [(62.1±30.4) points vs. (65.8±25.6) points] (all P>0.05). However, the LD group had lower chest-physical well-being scores than the mesh group [(40.6±9.7) points vs. (45.1±9.6) points, P<0.05], while breast satisfaction scores were higher in the LD group than in the mesh group [(68.0±17.8) points vs. (59.8±12.6) points, P<0.01]. Conclusion:Immediate breast reconstruction by both latissimus dorsi flap with implant and mesh with implant can improve patients’ psychosocial and sexual well-being by enhancing breast appearance. However, LD technique provides better breast satisfaction, while the mesh technique offers advantages in physical well-being of the chest wall and upper body. Surgeons should select the most appropriate breast reconstruction technique based on patients’ anatomical conditions, treatment history, and individual needs to optimize postoperative quality of life and satisfaction.
10.Comparison of clinical outcomes between latissimus dorsi flap with implant and mesh with implant for immediate breast reconstruction: a BREAST-Q assessment
Tinghong XIANG ; Lu YIN ; Tianyi NI ; Yiwen GAO ; Yingying WANG ; Xianglong ZU ; Shujie RUAN ; Wei YAN ; Zhechen ZHU ; Jingping SHI
Chinese Journal of Plastic Surgery 2025;41(7):710-718
Objective:To compare the clinical outcomes of immediate breast reconstruction using latissimus dorsi flap with implant versus mesh with implant based on BREAST-Q evaluation.Methods:From the clinical database of the First Affiliated Hospital of Nanjing Medical University, the patients who underwent immediate breast reconstruction after total mastectomy from January 2020 to December 2023 were selected as the research subjects. All breast reconstruction surgeries were performed by the same surgeon. Patients were divided into two groups according to surgical methods: the latissimus dorsi muscle flap combined with implant immediate breast reconstruction group (LD group) and the mesh combined with implant immediate breast reconstruction group (mesh group). Patients were followed up in outpatient clinics or by telephone one year after surgery. The BREAST-Q was used to evaluate the surgical outcomes of both groups from four dimensions: psychosocial well-being, sexual well-being, chest-physical well-being, and breast satisfaction. The score range for each dimension was 0-100, with higher scores indicating greater patient satisfaction with quality of life and surgical outcomes. Statistical analysis was performed using SPSS 22.0 software. Normally distributed measurement data were expressed as Mean ± SD, and comparisons between the two groups were performed using independent sample t-test. Count data were expressed as number of cases and percentages, and comparisons between groups were performed using chi-square test or Fisher’s exact test. P<0.05 was considered statistically significant. Results:A total of 123 patients were included, with 59 patients in the LD group and 64 patients in the mesh group. In the LD group, the mean age was (37.7±7.0) years, body mass index (BMI) was (22.6±2.6) kg/m 2, and clinical tumor staging showed 2, 22, 30, and 5 cases for stages 0, Ⅰ, Ⅱ, and Ⅲ, respectively. In the mesh group, the mean age was (39.1±7.0) years, BMI was (22.6±2.8) kg/m 2, and clinical tumor staging showed 1, 25, 38, and 0 cases for stages 0, Ⅰ, Ⅱ, and Ⅲ, respectively. There were no statistically significant differences between the two groups in baseline characteristics including age, BMI, and clinical tumor staging (all P>0.05). One year after surgery, the BREAST-Q result showed no statistically significant differences between the LD group and mesh group in psychosocial well-being [(83.0±19.8) points vs. (80.8±19.3) points] and sexual well-being [(62.1±30.4) points vs. (65.8±25.6) points] (all P>0.05). However, the LD group had lower chest-physical well-being scores than the mesh group [(40.6±9.7) points vs. (45.1±9.6) points, P<0.05], while breast satisfaction scores were higher in the LD group than in the mesh group [(68.0±17.8) points vs. (59.8±12.6) points, P<0.01]. Conclusion:Immediate breast reconstruction by both latissimus dorsi flap with implant and mesh with implant can improve patients’ psychosocial and sexual well-being by enhancing breast appearance. However, LD technique provides better breast satisfaction, while the mesh technique offers advantages in physical well-being of the chest wall and upper body. Surgeons should select the most appropriate breast reconstruction technique based on patients’ anatomical conditions, treatment history, and individual needs to optimize postoperative quality of life and satisfaction.

Result Analysis
Print
Save
E-mail